{"title":"解释药物使用中的社会经济不平等:来自伊朗的横断面分析。","authors":"Amin Torabipour, Touraj Harati Khalilabad, Zhila Najafpour, Marzieh Araban, Sajad Vahedi","doi":"10.5812/ijpr-129431","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite the favorable progress in the production of medicines, there is no significant access to these important health inputs among different socio-economic groups.</p><p><strong>Objectives: </strong>This study aimed to measure and explain socio-economic inequality in prescribed and non-prescribed medicine use in Iran.</p><p><strong>Methods: </strong>Data were obtained from a recent household survey on health services in Iran conducted in 2016. The Erreygers concentration index (ECI) was used to measure socio-economic inequality in the use of prescribed and non-prescribed medicines. In addition, Decomposition analysis was conducted to explain socio-economic inequality.</p><p><strong>Results: </strong>The ECI revealed pro-rich socio-economic inequality in prescribed medicine use (ECI = 0.067, SE = 0.010), indicating that prescribed medicine use was concentrated on the better-offs. On the other hand, this index showed pro-poor inequality in non-prescribed medicine use (ECI = -0.064, SE = 0.009). Decomposition analysis showed that economic status and place of residence were the main determinants of socio-economic inequality in prescribing medicines. These factors and the number of health care needs explained the majority of socio-economic inequality in non-prescribed medicine use.</p><p><strong>Conclusions: </strong>Despite previous positive beliefs, we found remarkable socio-economic inequality in the use of medicines in Iran. Facilitating access to pharmaceutical services for disadvantaged households and rural residents and promoting of national essential medicines list could be recommended against socio-economic inequality in the pharmaceutical market of Iran.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e129431"},"PeriodicalIF":1.8000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/68/ijpr-21-1-129431.PMC10024324.pdf","citationCount":"0","resultStr":"{\"title\":\"Explanation of Socio-economic Inequality in Medicine Use: A Cross-sectional Analysis from Iran.\",\"authors\":\"Amin Torabipour, Touraj Harati Khalilabad, Zhila Najafpour, Marzieh Araban, Sajad Vahedi\",\"doi\":\"10.5812/ijpr-129431\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Despite the favorable progress in the production of medicines, there is no significant access to these important health inputs among different socio-economic groups.</p><p><strong>Objectives: </strong>This study aimed to measure and explain socio-economic inequality in prescribed and non-prescribed medicine use in Iran.</p><p><strong>Methods: </strong>Data were obtained from a recent household survey on health services in Iran conducted in 2016. The Erreygers concentration index (ECI) was used to measure socio-economic inequality in the use of prescribed and non-prescribed medicines. In addition, Decomposition analysis was conducted to explain socio-economic inequality.</p><p><strong>Results: </strong>The ECI revealed pro-rich socio-economic inequality in prescribed medicine use (ECI = 0.067, SE = 0.010), indicating that prescribed medicine use was concentrated on the better-offs. On the other hand, this index showed pro-poor inequality in non-prescribed medicine use (ECI = -0.064, SE = 0.009). Decomposition analysis showed that economic status and place of residence were the main determinants of socio-economic inequality in prescribing medicines. These factors and the number of health care needs explained the majority of socio-economic inequality in non-prescribed medicine use.</p><p><strong>Conclusions: </strong>Despite previous positive beliefs, we found remarkable socio-economic inequality in the use of medicines in Iran. Facilitating access to pharmaceutical services for disadvantaged households and rural residents and promoting of national essential medicines list could be recommended against socio-economic inequality in the pharmaceutical market of Iran.</p>\",\"PeriodicalId\":14595,\"journal\":{\"name\":\"Iranian Journal of Pharmaceutical Research\",\"volume\":\"21 1\",\"pages\":\"e129431\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/68/ijpr-21-1-129431.PMC10024324.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Journal of Pharmaceutical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5812/ijpr-129431\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5812/ijpr-129431","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景:尽管在药品生产方面取得了有利进展,但不同的社会经济群体并没有大量获得这些重要的保健投入。目的:本研究旨在衡量和解释伊朗处方药和非处方药使用中的社会经济不平等。方法:数据来自最近于2016年在伊朗进行的卫生服务家庭调查。埃雷格斯浓度指数(ECI)用于衡量处方药和非处方药使用中的社会经济不平等。此外,对社会经济不平等现象进行了分解分析。结果:ECI揭示了处方用药的亲富社会经济不平等(ECI = 0.067, SE = 0.010),表明处方用药集中于较富裕人群;另一方面,该指数显示非处方药使用的亲穷人不平等(ECI = -0.064, SE = 0.009)。分解分析表明,经济地位和居住地是处方中社会经济不平等的主要决定因素。这些因素和保健需求的数量解释了非处方药使用方面的大部分社会经济不平等。结论:尽管以前的积极信念,我们发现在伊朗的药物使用显著的社会经济不平等。针对伊朗药品市场的社会经济不平等现象,可建议促进弱势家庭和农村居民获得药品服务,并推广国家基本药物清单。
Explanation of Socio-economic Inequality in Medicine Use: A Cross-sectional Analysis from Iran.
Background: Despite the favorable progress in the production of medicines, there is no significant access to these important health inputs among different socio-economic groups.
Objectives: This study aimed to measure and explain socio-economic inequality in prescribed and non-prescribed medicine use in Iran.
Methods: Data were obtained from a recent household survey on health services in Iran conducted in 2016. The Erreygers concentration index (ECI) was used to measure socio-economic inequality in the use of prescribed and non-prescribed medicines. In addition, Decomposition analysis was conducted to explain socio-economic inequality.
Results: The ECI revealed pro-rich socio-economic inequality in prescribed medicine use (ECI = 0.067, SE = 0.010), indicating that prescribed medicine use was concentrated on the better-offs. On the other hand, this index showed pro-poor inequality in non-prescribed medicine use (ECI = -0.064, SE = 0.009). Decomposition analysis showed that economic status and place of residence were the main determinants of socio-economic inequality in prescribing medicines. These factors and the number of health care needs explained the majority of socio-economic inequality in non-prescribed medicine use.
Conclusions: Despite previous positive beliefs, we found remarkable socio-economic inequality in the use of medicines in Iran. Facilitating access to pharmaceutical services for disadvantaged households and rural residents and promoting of national essential medicines list could be recommended against socio-economic inequality in the pharmaceutical market of Iran.
期刊介绍:
The Iranian Journal of Pharmaceutical Research (IJPR) is a peer-reviewed multi-disciplinary pharmaceutical publication, scheduled to appear quarterly and serve as a means for scientific information exchange in the international pharmaceutical forum. Specific scientific topics of interest to the journal include, but are not limited to: pharmaceutics, industrial pharmacy, pharmacognosy, toxicology, medicinal chemistry, novel analytical methods for drug characterization, computational and modeling approaches to drug design, bio-medical experience, clinical investigation, rational drug prescribing, pharmacoeconomics, biotechnology, nanotechnology, biopharmaceutics and physical pharmacy.